Omniscient Neurotechnology (o8t)

We create enterprise grade clinical and research solutions applicable to a variety of brain-related disorders, including depression, chronic pain, cancer, bi-polar disorder, Alzheimer’s, dementia, and PTSD, with the goal of bringing predictive analytics to the world faster. We are a data company and aim to radically change the care of patients with brain disease by turning loose Machine learning/AI and big data to actually provide useful information to doctors. This involves both facilitating research, and providing high quality data based guidance to clinicians.

https://o8t.com

51-200 employees

Growth Trajectory

Omniscient Neurotechnology has significant growth potential through expanding the applications of Quicktome to new clinical areas, furthering AI and machine learning capabilities, and establishing strategic partnerships with hospitals and research institutions. The company's focus on personalized brain mapping positions it well to address the growing need for precision in neurosurgery and brain health management, indicating a positive growth trajectory.

Technical Challenges

Generating accurate tractography for complex fiber orientations.

Refining surgical strategies based on connectomic analysis.

Preserving neurocognitive functions during surgery.

Maximizing onco-functional balance during surgery.

Handling and analyzing large volumes of connectomic data.

Processing noise related to cerebral edema, subject motion correction, gradient distortion correction.

Tech Stack

AIMRIrs-fMRIfMRIDTICloud computingMachine learningConnectomicsGraph theoryDiffusion Tensor ImagingTranscranial Magnetic Stimulation (TMS)HCP ParcellationDWI (Diffusion-weighted imaging)Constrained Spherical Deconvolution (CSD)

Team Size

Research and development teams

Distribution partners

Collaborative research with global institutions

Key Risks

The company faces the risk of technical hurdles in accurately mapping complex brain functions.

Competition from other companies in the brain mapping and neurotechnology space may intensify.

Regulatory requirements for medical devices, such as FDA clearance, could pose challenges.

Reliance on AI and machine learning algorithms may present risks related to data handling and algorithm bias.

Opportunities

Advancements in AI and machine learning present an opportunity to enhance brain mapping accuracy and visualization.

Expanding the application of connectomics to mental health disorders and neurorehabilitation could open new markets.

Collaborations with research institutions can drive innovation and validation of brain network biomarkers.

Integration with other medical devices and technologies can enhance the utility of Quicktome in clinical settings.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes